Clinical trial of EIDD-2801 to cure COVID-19 kicks off

EIDD-2801 drug, which has shown promising results in reducing lung damage, was licensed by the Food and Drug Administration (FDA) and has been moved for the first stage of clinical trials.

Iran PressEurope: EIDD-2801 drug can be taken as a pill and can be properly absorbed to travel to the lungs.

The drug was found to inhibit virus production and proliferation by mimicking ribonucleosides – the primary components of Ribonucleic acid (RNA) molecules – causing debilitating errors when the drugs are incorporated into viral RNA during replication, preventing the spread of the virus.

The novel contagious virus has infected more than 2.3 million people with COVID-19 and caused above 161,000 deaths in a worldwide pandemic.

The total death toll from the novel coronavirus disease (COVID-19) has exceeded 100,000 in hardest-hit Europe on Saturday.

Europe accounts for a total of 100,510 deaths -- nearly two-thirds of the 157,539 fatalities worldwide, according to an AFP tally, while nearly a quarter of deaths have come in the United States.

104/205/201

Read More:

Europe's virus death toll surpasses 100,000; Protests surged in US

Global Coronavirus deaths hit 154,000; infection cases close to 2, 250,000